Abstract: The present invention belongs to the technical field of audio equipment, and particularly relates to a wireless microphone device and a use method therefor. In the wireless microphone device, a main control unit controls a transmitter working mode in which an input unit, an output unit, a time code unit, a conversion modulation unit, a storage unit and a radio-frequency unit work together; or a receiver working mode in which the input unit, the output unit, the time code unit, the conversion modulation unit and the radio frequency unit work together; or a time code generator working mode in which the output unit and the time code unit work together; or a sound recorder working mode in which the input unit, the time code unit, the conversion modulation unit and the storage unit work together.

Abstract: The embodiment of the present disclosure provides a time code synchronization method, which includes following steps of: determining a target master node and one or more target slave nodes of a network system among the plurality of nodes; periodically sending a data packet to the one or more target slave nodes by the target master node, wherein the data packet includes a first time code and serial number information of the target master node; compensating the first time code according to the serial number information to obtain a second time code, and synchronizing the second time code by the one or more target slave nodes.

Abstract: The present invention belongs to the technical field of audio equipment, and particularly relates to a wireless microphone device and a use method therefor. In the wireless microphone device, a main control unit controls a transmitter working mode in which an input unit, an output unit, a time code unit, a conversion modulation unit, a storage unit and a radio-frequency unit work together; or a receiver working mode in which the input unit, the output unit, the time code unit, the conversion modulation unit and the radio frequency unit work together; or a time code generator working mode in which the output unit and the time code unit work together; or a sound recorder working mode in which the input unit, the time code unit, the conversion modulation unit and the storage unit work together.

Abstract: The embodiment of the present disclosure provides a time code synchronization method, which includes following steps of: determining a target master node and one or more target slave nodes of a network system among the plurality of nodes; periodically sending a data packet to the one or more target slave nodes by the target master node, wherein the data packet includes a first time code and serial number information of the target master node; compensating the first time code according to the serial number information to obtain a second time code, and synchronizing the second time code by the one or more target slave nodes.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)actylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: Disclosed are an EGFR inhibitor free base or acid salt polycrystalline form, a preparation method therefor, and an application thereof. The present invention specifically relates to an N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide free base or acid salt polycrystalline form, a preparation method therefor, and an application of the polycrystalline form in preparing a drug for treating an EGFR mutant activity-mediated disease. The present invention is used for inhibiting the activity of an L858R EGFR mutant, a T790M EGFR mutant and an exon 19 deletion activating mutant etc., may be widely applied in preventing and treating cancer, especially non-small cell lung cancer and other related diseases, and is expected to develop into a new generation of EGFR inhibitors.

Abstract: A bi-material connecting rod is disclosed herein. The connecting rod includes a crank end that formed from a first material, and a shank connected to the crank end that is formed from a second material. The connecting rod further includes a pin end adjacent to the shank and opposite from the crank end that can be formed from the first material, second powder-metal material, or a third material. Also disclosed herein is a method for making a bi-material connecting rod.

Abstract: A process of forming powder metal components which minimizes decarburization and oxidation of the component prior to final forging. The process begins by molding powder metal material into a preform configuration. The preform is delubricated to extract lubricant found in the pores of the preform. Passing the preform through a shot peening operation closes a majority of the surface pores creating a densified layer within which interconnected pores are eliminated. Following post-delubrication peening (PDP), the component is sintered and then forged into its final configuration.